Tirzepatide Use in People With Obesity and Type 1 Diabetes

NCT07096908 on ClinicalTrials.gov · last registry update 2026-04-20

Recruiting now, toward 60 participants. Due to report 25 February 2028, alongside 25 other tracked readouts that quarter. Primary outcome, as filed: Bodyweight. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P4
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Dasman Diabetes Institute
Sponsor type: Other
Enrollment: 60
Started: 2025-07-31
Primary completion: 2028-02-25 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Bodyweight

Conditions studied

Type1diabetes · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.